WO2005034840A8 - Identification of kinase inhibitors - Google Patents

Identification of kinase inhibitors

Info

Publication number
WO2005034840A8
WO2005034840A8 PCT/US2003/029870 US0329870W WO2005034840A8 WO 2005034840 A8 WO2005034840 A8 WO 2005034840A8 US 0329870 W US0329870 W US 0329870W WO 2005034840 A8 WO2005034840 A8 WO 2005034840A8
Authority
WO
WIPO (PCT)
Prior art keywords
identification
kinase inhibitors
inhibitors
protein kinase
inactive conformation
Prior art date
Application number
PCT/US2003/029870
Other languages
French (fr)
Other versions
WO2005034840A2 (en
WO2005034840A3 (en
Inventor
John C Prescott
Andrew Braisted
Original Assignee
Sunesis Pharmaceuticals Inc
Morrow Joelle
John C Prescott
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunesis Pharmaceuticals Inc, Morrow Joelle, John C Prescott filed Critical Sunesis Pharmaceuticals Inc
Priority to EP03752561A priority Critical patent/EP1670422A4/en
Priority to PCT/US2003/029870 priority patent/WO2005034840A2/en
Priority to AU2003270848A priority patent/AU2003270848A1/en
Priority to CA002539064A priority patent/CA2539064A1/en
Publication of WO2005034840A2 publication Critical patent/WO2005034840A2/en
Publication of WO2005034840A8 publication Critical patent/WO2005034840A8/en
Publication of WO2005034840A3 publication Critical patent/WO2005034840A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns the identification of protein kinase inhibitors that preferentially bind to the inactive conformation of a target protein kinase. The inhibitors are identified by locking the target protein kinase in an inactive conformation, and using Tethering to identify inhibitors preferentially targeting the inactive conformation.
PCT/US2003/029870 2003-09-17 2003-09-17 Identification of kinase inhibitors WO2005034840A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03752561A EP1670422A4 (en) 2003-09-17 2003-09-17 Identification of kinase inhibitors
PCT/US2003/029870 WO2005034840A2 (en) 2003-09-17 2003-09-17 Identification of kinase inhibitors
AU2003270848A AU2003270848A1 (en) 2003-09-17 2003-09-17 Identification of kinase inhibitors
CA002539064A CA2539064A1 (en) 2003-09-17 2003-09-17 Identification of kinase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/029870 WO2005034840A2 (en) 2003-09-17 2003-09-17 Identification of kinase inhibitors

Publications (3)

Publication Number Publication Date
WO2005034840A2 WO2005034840A2 (en) 2005-04-21
WO2005034840A8 true WO2005034840A8 (en) 2006-04-20
WO2005034840A3 WO2005034840A3 (en) 2006-10-05

Family

ID=34434214

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/029870 WO2005034840A2 (en) 2003-09-17 2003-09-17 Identification of kinase inhibitors

Country Status (4)

Country Link
EP (1) EP1670422A4 (en)
AU (1) AU2003270848A1 (en)
CA (1) CA2539064A1 (en)
WO (1) WO2005034840A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
BRPI0719883A2 (en) 2006-10-09 2015-05-05 Takeda Pharmaceutical Kinase Inhibitors
SG179172A1 (en) * 2009-09-16 2012-04-27 Avila Therapeutics Inc Protein kinase conjugates and inhibitors
MX2012007684A (en) 2009-12-30 2012-10-05 Avila Therapeutics Inc Ligand-directed covalent modification of protein.
US20130143911A1 (en) 2010-06-09 2013-06-06 Dana-Farber Cancer Institute, Inc. MEK1 Mutation Conferring Resistance to RAF and MEK Inhibitors
GB201614152D0 (en) 2016-08-18 2016-10-05 Imp Innovations Ltd Assay
US20220265669A1 (en) * 2019-02-25 2022-08-25 Albert Einstein College Of Medicine Compounds useful for inhibiting raf dimers
CN116434828B (en) * 2023-04-17 2024-03-26 深圳新锐基因科技有限公司 Method and device for introducing dynamic disulfide bonds of protein molecules based on computational structure biology

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002225731B2 (en) * 2000-11-21 2005-04-14 Sunesis Pharmaceuticals, Inc. An extended tethering approach for rapid identification of ligands
WO2003014308A2 (en) * 2001-08-07 2003-02-20 Sunesis Pharmaceuticals, Inc. Cysteine mutants and methods for detecting ligand binding to biological molecules
JP2005534286A (en) * 2002-03-21 2005-11-17 サネシス ファーマシューティカルズ， インコーポレイテッド Identification of kinase inhibitors

Also Published As

Publication number Publication date
CA2539064A1 (en) 2005-04-21
WO2005034840A2 (en) 2005-04-21
EP1670422A4 (en) 2007-08-01
AU2003270848A1 (en) 2005-04-27
EP1670422A2 (en) 2006-06-21
WO2005034840A3 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
WO2003081210A3 (en) Identification of kinase inhibitors
WO2008121742A3 (en) Inhibitors of bruton's tyrosine kinase
AP2005003383A0 (en) Aminoheteroaryl compounds as protein kinase inhibitors.
AP2139A (en) 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors.
WO2006004884A3 (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
AP2005003353A0 (en) Diazepinoindole derivatives as kinase inhibitors.
DE602004010206D1 (en) Dipeptidyl peptidase inhibitors.
ATE525377T1 (en) IMIDAZOÄ1,5-AÜPYRAZINE AS TYROSINKINASE INHIBITORS
WO2007149523A3 (en) Hexahydro-isoalpha acid based protein kinase modulation cancer treatment
DE122012000043I1 (en) Pyrrolo [2,3-B] pyridine derivatives as protein kinase inhibitors.
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
DE60313872D1 (en) PYRAZOLOE1,5-ATPYRIMIDINES AS INHIBITORS CYCLINE-DEPENDENT KINASES
WO2007075525A3 (en) Combination of an iap-inhibitor and a taxane7
WO2007133290A3 (en) Anti-ox40l antibodies and methods using same
WO2007139849A3 (en) Modified nucleic acid nanoarrays and uses therefor
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
WO2005087793A3 (en) Immunostimulatory compositions and uses thereof
WO2007050795A3 (en) Transglutaminase inhibitors and methods of use thereof
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
EP1773843A4 (en) Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors
EP1922086A4 (en) Targeted protein kinase c inhibitors and uses thereof
WO2007076174A3 (en) Methods, systems, and apparatus for multi-domain markers
DE60216641D1 (en) POLYMORPH OF 4-Ä2-Ä4-Ä1- (2-ETHOXYETHYL) -1H-BENZIMIDAZOLE-2-YLÜ-1-PIPERIDINYLÜETHYLÜ-ALPHA, ALPHA-DIMETHYLBENZOLIC ACIDIC ACID
WO2007022042A3 (en) Combinations comrising a protein kinase inhibitor being a pyrimidylaminobξnzamide compound and a hsp90 inhibitor such as 17-aag
WO2005034840A3 (en) Identification of kinase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2539064

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003270848

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003752561

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 16/2005 UNDER (72, 75) REPLACE "PRESCOOT, JOHN, C." BY "PRESCOTT, JOHN, C."

WWP Wipo information: published in national office

Ref document number: 2003752561

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP